Alaleh Nouri, who serves as Executive Vice President and Chief Legal Officer at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold a total of 5,363 shares of the company's common stock on March 19, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The combined proceeds from the two transactions amounted to about $139,230. The first block of 3,031 shares was sold at prices spanning $25.025 to $26.020. The second block comprised 2,332 shares sold at prices between $26.025 and $26.450. The sales were executed pursuant to a Rule 10b5-1 trading plan that Nouri adopted on June 4, 2025. Following these dispositions, Nouri's direct holdings in PROCEPT total 105,354 shares.
At the time of the filing, PROCEPT's shares were trading at $25.68, representing a 56% decline over the past 12 months. The filing and the broader market context arrive as the company pursues commercial expansion for its robotic-assisted benign prostatic hyperplasia (BPH) therapy.
Corporate developments and commercial activity
PROCEPT has begun commercial activity in the United Kingdom with the launch of its HYDROS Robotic System. The system delivers Aquablation therapy for BPH using real-time ultrasound imaging interpreted by artificial intelligence, and the company has signaled plans for further international expansion through 2026. Management also expanded the board of directors by appointing Daniel Puckett to the board and its audit committee, increasing the board's size from eight to nine members.
Analyst coverage and outlook
Recent analyst moves present a mixed picture. Baird initiated coverage on PROCEPT with a Neutral rating and a $30 price target. Truist Securities lowered its price target to $30 from $47 while maintaining a Buy rating, citing reduced 2027 forecasts. TD Cowen reiterated a Buy rating with a $34 price target and noted confidence in the company's recent commercial adjustments despite the prior decline in share price. The firm continues to highlight the company's traction in robotic-assisted BPH therapy as a positive element of its commercial story.
What this means for markets and stakeholders
The insider sale is a disclosed, rule-compliant transaction executed under an existing trading plan and does not, on its face, introduce any new governance or compliance claims. Investors and market participants will likely weigh the insider activity alongside the company's international rollout, board changes, and the recent analyst revisions when assessing near-term valuation and execution risk.
Given the mix of product launches, board expansion and divergent analyst views, market attention will remain focused on execution of the HYDROS commercial rollout and how updated forecast assumptions translate into future financial performance.